CARSGEN-B News

Keji Pharmaceutical-B (02171.HK): CT053 commercialization implementation looks forward to overseas breakthroughs

浙商證券Apr 25 13:26

Keji Pharmaceutical (2171.HK): Seckaize has been approved for marketing and commercial release can be expected

國泰君安Apr 7 00:00

Keji Pharmaceutical (2171.HK): Sekai Sekai is listed and is looking forward to commercialization in 2024

西南證券Mar 26 00:00

Keji Pharmaceutical-B (02171.HK): CT053 approved for listing, optimistic about MM's commercialization prospects

東吳證券Mar 3 00:00

Keji Pharmaceutical-B (02171.HK): BCMACAR-T China approved for listing and reached commercialization milestone

國盛證券Mar 1 00:00

Keji Pharmaceutical-B (02171.HK): CLAUDIN18.2CAR-T Case Report on Pancreatic Cancer Treatment Published in International Academic Journals

國盛證券Sep 27, 2023 20:32

Keji Pharmaceutical-B (02171.HK): BCMA CAR-T is about to be approved CLAUDIN18.2 The critical clinical progress of CAR-T is progressing smoothly

東吳證券Aug 25, 2023 13:52

Keji Pharmaceutical-B (2171.HK): Product development continues to advance, core products are about to be approved

國泰君安Aug 25, 2023 08:36

Keji Pharmaceutical (02171): Domestic commercialization is imminent and can be expected overseas

浙商證券Aug 24, 2023 16:02

Keji Pharmaceutical-B (02171.HK): Continuing to promote commercialization of core products and technological upgrading

國聯證券Aug 24, 2023 08:16

Keji Pharmaceutical-B (02171.HK): CAR-T U.S. production capacity ready solid tumors are worth looking forward to

國金證券Aug 24, 2023 00:00

Keji Pharmaceutical (2171.HK): CT053 is about to be launched and global production capacity continues to expand

西南證券Aug 23, 2023 00:00

Keji Pharmaceutical-B (02171.HK): Commercialization of BCMACAR-T will reach solid tumors or break through

國金證券May 28, 2023 00:00

Keji Pharmaceutical (2171.HK): CT053 is about to be marketed and we expect the solid tumor CAR-T to break out

西南證券Mar 24, 2023 00:00

Keji Pharmaceutical-B (02171.HK): Product development progress continues to advance

國泰君安Mar 24, 2023 00:00

Keji Pharmaceutical-B (02171.HK) 2022 Report Review: Hematoma and Solid Tumor Pipelines Go Hand in Hand to Advance Monoclonal Antibody and Roche Achieved

興業證券Mar 23, 2023 13:37

Keji Pharmaceutical (02171.HK): Commercialization is imminent and we expect progress in solid tumors

浙商證券Mar 23, 2023 00:00

Keji Pharmaceutical-B (02171.HK): Solid tumors, CAR-T is deeply involved in R&D platforms with rich innovation pipelines

東北證券Mar 17, 2023 00:00

Keji Pharmaceutical (2171.HK): Global leader in solid cancer CAR-T with excellent technology

國聯證券Feb 3, 2023 00:00

Koji Pharmaceutical-B (2171.HK) Incident Review: Win-win Cooperation in East China Helps CT053 Domestic Commercialization

國泰君安Jan 19, 2023 14:27